Matthew McClure
Plus aucun poste en cours
Fortune : 54 506 $ au 31/05/2024
Provenance du réseau au premier degré de Matthew McClure
| Entité | Type d'entité | Industrie | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 10 | |
Alios BioPharma, Inc.
 Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA.
5
| Extinct | Pharmaceuticals: Major | 5 |
Second Genome, Inc.
 Second Genome, Inc. BiotechnologyHealth Technology Second Genome, Inc. develops microbiome-based therapeutic products. It offers phyclochip community, 16S sequencing community analysis, whole metagenomic profiling, nucleic acid isolation, inferred function and custom informatics services. The company was founded in 2009 by Corey S. Goodman, Janet A. Warrington, Todd Z. DeSantis, John Hulls and Gary Andersen and is headquartered in South San Francisco, CA.
2
| Holding Company | Biotechnology | 2 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Matthew McClure via son réseau personnel
| Société | Secteur | Personnes liées | Poste principal |
|---|---|---|---|
| INTERMUNE INC | Biotechnology | Chief Tech/Sci/R&D Officer Corporate Officer/Principal General Counsel | |
| University of California, Berkeley | College/University | Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
Kanyos Bio, Inc.
 Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Kanyos Bio, Inc. engages in the provision of immune tolerance technology solutions. It develops antigen-specific for treatment of type-1 diabetes and celiac disease. The company was founded by Jeffrey Hubbell, Stephan Kontos, Oscar Buset, Kristen M. Lorentz, and David A. Lowin in 2015 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| IO BIOTECH, INC. | Biotechnology | Director/Board Member Director/Board Member | |
| ADVERUM BIOTECHNOLOGIES, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| FLEXION THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
| Stanford University | College/University | Doctorate Degree Doctorate Degree | |
Novo Ventures (US), Inc.
 Novo Ventures (US), Inc. Investment ManagersFinance Novo Ventures (US), Inc. is a venture capital firm located in San Francisco. The firm is a subsidiary of Novo A/S and their ultimate parent is Novo Nordisk Fonden. | Investment Managers | Private Equity Investor Corporate Officer/Principal | |
| JOHNSON & JOHNSON | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Anokion SA
 Anokion SA Medical/Nursing ServicesHealth Services Anokion SA provides technology for retraining white blood cells to induce therapeutic immune tolerance. The firm?s approach to antigen-specific immune tolerance can be translated to virtually any protein in numerous clinical indications. The company was founded by Jerffery Hubbell, Melody Swartz, Stephan Kontos, Oscar Buset, Kristen M. Lorentz and David A. Lowin and is headquartered in Ecublens, Switzerland. | Medical/Nursing Services | Director/Board Member Director/Board Member | |
| ALX ONCOLOGY HOLDINGS INC. | Biotechnology | Director/Board Member | |
Inception Sciences, Inc.
 Inception Sciences, Inc. Pharmaceuticals: MajorHealth Technology Inception Sciences, Inc. provides small molecule pharmaceutical incubator services. Its focus is on creating therapies with transformative potential to address diseases and disorders. The company creates new companies in partnership with pioneering academic researchers and major biopharmaceutical companies, which provide funding and a path to liquidity through pre-negotiated acquisitions. The company was founded in 2011 and is headquartered in San Diego, CA. | Pharmaceuticals: Major | Director/Board Member | |
| AUDENTES THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
Euro Ventures 4, Inc.
 Euro Ventures 4, Inc. Investment ManagersFinance Part of Versant Venture Management LLC, Euro Ventures 4, Inc. is a private equity fund. The company is based in Menlo Park, CA. The company was founded by Thomas F. Woiwode. | Investment Managers | Founder | |
Antipodean Pharmaceuticals, Inc.
 Antipodean Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Antipodean Pharmaceuticals, Inc. manufactures pharmaceutical products and provides pre clinical services. Its product MitoQ, which blocks mitochondrial oxidative damage and prevents cell death. The company was founded in 2002 and is headquartered in Menlo Park, CA. | Pharmaceuticals: Major | Director/Board Member | |
| CYMABAY THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
| CRISPR THERAPEUTICS AG | Biotechnology | Director/Board Member | |
Inception IBD, Inc.
 Inception IBD, Inc. Miscellaneous Commercial ServicesCommercial Services Inception IBD, Inc. provides therapeutics services. It creates new companies in partnership with pioneering academic researchers and major biopharmaceutical companies, which provide funding and a path to liquidity through pre-negotiated acquisitions. The company was founded by Eric Ogier-Denis, Yoram Bouhnik, Xavier Treton and Jacques Mizrahi in 2011 and is headquartered in San Diego, CA. | Miscellaneous Commercial Services | Director/Board Member | |
Vividion Therapeutics, Inc.
 Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | Miscellaneous Commercial Services | Director/Board Member | |
| GRITSTONE BIO, INC. | Biotechnology | Director/Board Member | |
| XENOPORT, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Jecure Therapeutics, Inc.
 Jecure Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Jecure Therapeutics, Inc. provides therapeutic services for the treatment of non-alcoholic steatohepatitis (NASH) and liver fibrosis. The company was founded by Ariel Feldstein in 2015 and is headquartered in San Diego, CA. | Miscellaneous Commercial Services | Director/Board Member | |
Versant Venture Capital VI (Canada) LP
 Versant Venture Capital VI (Canada) LP Investment ManagersFinance Versant Venture Capital VI (Canada) LP operates as a pooled investment fund. The company is headquartered in San Francisco, CA. | Investment Managers | Director/Board Member | |
TempestTx, Inc.
 TempestTx, Inc. BiotechnologyHealth Technology TempestTx, Inc. is a clinical stage biotechnology company which engages in advancing small molecule therapeutics that modulate anti-tumor pathways. The company is headquartered in South San Francisco, CA. | Biotechnology | Director/Board Member | |
CODA Biotherapeutics, Inc.
 CODA Biotherapeutics, Inc. Medical SpecialtiesHealth Technology CODA Biotherapeutics, Inc. engages in the development of chemo genetic neuromodulation platform for the treatment of severe neurological disorders. The company was founded by Mitchell H. Finer, Allan Basbaum, Nicholas Boulis, Joseph Glorioso III and Kenneth P. Greenberg in 2014 and is headquartered in South San Francisco, CA. | Medical Specialties | Director/Board Member | |
| PASSAGE BIO, INC. | Biotechnology | Director/Board Member | |
| APOLLO ENDOSURGERY, INC. | Medical Specialties | Director/Board Member | |
Therachon SAS
 Therachon SAS BiotechnologyHealth Technology TherAchon SAS provides biotechnology services. It specializes in research and development for achondroplasia and its associated complications. The company was founded by Elvire Gouze in 2014 and is headquartered in Biot, France. | Biotechnology | Chairman | |
| DYADIC INTERNATIONAL, INC. | Medical/Nursing Services | President | |
MacuLogix, Inc.
 MacuLogix, Inc. Medical/Nursing ServicesHealth Services MacuLogix, Inc. engages in the early detection and tracking of retinal diseases. Its AdaptDx is the first practical measurement tool for dark adaptation which provides doctors with an easy-to-use functional test similar to routine perimetry testing for glaucoma. The company also provides macular degeneration services. The company was founded by John G. Edwards and Gregory R. Jackson in 2004 and is headquartered in Harrisburg, PA. | Medical/Nursing Services | Director/Board Member | |
Alx Oncology Ltd.
 Alx Oncology Ltd. Pharmaceuticals: MajorHealth Technology Alx Oncology Ltd. operates as biotechnology company developing immuno-oncology therapies for cancer. The company was founded by Kipp Weiskopf and Jaume Pons in 2015 and is headquartered in Ireland, Dublin. | Pharmaceuticals: Major | Director/Board Member | |
| HARMONY BIOSCIENCES HOLDINGS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Vivo Capital LLC
 Vivo Capital LLC Investment ManagersFinance Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California. | Investment Managers | Private Equity Investor | |
| CRINETICS PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
| INSTIL BIO, INC. | Biotechnology | Director/Board Member | |
Novo Holdings AS (Denmark)
 Novo Holdings AS (Denmark) Financial ConglomeratesFinance Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | Financial Conglomerates | Corporate Officer/Principal | |
| Vivo Co-Invest (S) LP | Director/Board Member | ||
Ocelot Bio, Inc.
 Ocelot Bio, Inc. Pharmaceuticals: MajorHealth Technology Ocelot Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on improving outcomes for patients with end-stage liver disease (ESLD), particularly those suffering from hepatorenal syndrome with acute kidney injury (HRS-AKI) and refractory ascites. The company is based in San Diego, CA. The company is developing therapeutic peptides to treat complications of decompensated cirrhosis, a condition in which the liver is scarred and permanently damaged, leading to liver failure. HRS-AKI is a life-threatening consequence of portal hypertension, which causes a significant drop in arterial pressure and renal perfusion. Ocelot Bio is in early-stage development of OCE-205 for the treatment of ascites, a complication of ESLD-induced portal hypertension that leads to the accumulation of fluid in the peritoneal cavity. The company was founded by Geoffrey Harris, and Katherine Vega Stultz has been the CEO of the company since 2022. | Pharmaceuticals: Major | Director/Board Member | |
| State University of New York at Buffalo | College/University | Undergraduate Degree | |
Novo Holdings A/S (Investment Company)
 Novo Holdings A/S (Investment Company) Financial ConglomeratesFinance Novo Holdings A/S (Investment Company) (Novo Holdings-IC) is the investment portfolio division of Novo Holdings A/S, a holding company headquartered in Hellerup, Denmark. They are ultimately owned by Novo Nordisk Fonden (Novo Nordisk Foundation). Founded in 1999, Novo Holdings-IC manages a broad portfolio of the Foundation’s financial assets. | Financial Conglomerates | Corporate Officer/Principal | |
| University of California, Riverside | College/University | Doctorate Degree | |
| Massachusetts Institute of Technology | College/University | Graduate Degree | |
Genencor International, Inc.
 Genencor International, Inc. BiotechnologyHealth Technology Genencor International, Inc. develops and manufactures enzyme product solutions for industrial, agricultural and health care markets. It finds genes and alters their proteins for use in cleaning, textile, health care, food and animal feed products using gene discovery, molecular evolution, functional genomics and immunology techniques. The company also develops solutions for the biofuels, biodefense and biosafety industries. Genencor International was founded in 1982 and is located in Rochester, NY. | Biotechnology | Corporate Officer/Principal |
Statistiques
Internationale
| Etats-Unis | 41 |
| Suisse | 5 |
| Danemark | 4 |
| France | 2 |
| Allemagne | 2 |
Sectorielle
| Health Technology | 31 |
| Finance | 8 |
| Consumer Services | 5 |
| Commercial Services | 5 |
| Health Services | 4 |
Opérationnelle
| Director/Board Member | 117 |
| Corporate Officer/Principal | 46 |
| Independent Dir/Board Member | 34 |
| Chairman | 19 |
| Chief Tech/Sci/R&D Officer | 15 |
Relations les plus connectées
| Insiders | |
|---|---|
| Heath Lukatch | 43 |
| Thomas Woiwode | 39 |
| Jack Nielsen | 38 |
| Jim Scopa | 26 |
| Bridget Martell | 19 |
| Lawrence Blatt | 13 |
| Kathleen Glaub | 13 |
| Glenn E. Nedwin | 10 |
| Lesley Calhoun | 9 |
| Leonid Beigelman | 8 |
| Anupama Hoey | 8 |
| Jordyn Tarazi | 5 |
| Lucinda Quan | 5 |
| John Fry | 3 |
- Bourse
- Insiders
- Matthew McClure
- Connexions Sociétés
